NYSE · CIK 0001237831
GMED GLOBUS MEDICAL INC
Insider trading from SEC Form 4. Last filing Mar 28, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Signals
Open-market buys and sells at GLOBUS MEDICAL INC, scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 19Weak | sell10b5-1 | RHOADS ANN D director | $590k | 7,500 | -17% | - | |
| 32Weak | sell10b5-1 | Pfeil Keith W COO, CFO | $1.3M | 14,167 | -100% | - | |
| 27Weak | sell 410b5-1 | Huller Kelly SVP, GC, Corporate Secretary | $218k | 2,500 | -100% | - | |
| 35Weak | sell 410b5-1 | Davidar David D director | $3.4M | 40,000 | -7% | - | |
| 50Moderate | sell 410b5-1 | Scavilla Daniel T President, CEO | $11M | 130,000 | -100% | - | |
| 60Notable | sell 4 | Lemaitre Dan director | $1.2M | 14,375 | -108% | - | |
| 43Moderate | sell 210b5-1 | Scavilla Daniel T President, CEO | $4.8M | 60,000 | -100% | - | |
| 24Weak | sell 210b5-1 | Huller Kelly SVP, GC, Corporate Secretary | $405k | 5,000 | -100% | - | |
| 28Weak | sell 210b5-1 | Davidar David D director | $3.8M | 50,000 | -9% | - | |
| 7Weak | sell 210b5-1 | Huller Kelly SVP, GC, Corporate Secretary | $563k | 7,500 | - | - |
Congressional trades
6 trades in GMED disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | GMED Globus Medical, Inc. Class A Common Stock | $15k to $50k | Aug 19, 2026 | 22 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | GMED Globus Medical, Inc. Class A Common Stock | $1,001 to $15k | Mar 3, 2026 | 35 days after the trade |
| Lisa C. McClain House · R-MI | Partial sale | GMED Globus Medical, Inc. Class A Common Stock | $1,001 to $15k | Jun 24, 2025 | 50 days after the trade |
| Lisa C. McClain House · R-MI | Sale | GMED Globus Medical, Inc. Class A Common Stock | $1,001 to $15k | Jul 10, 2025 | 34 days after the trade |
| Lisa C. McClain House · R-MI | Purchase | GMED Globus Medical, Inc. Class A Common Stock | $1,001 to $15k | Jun 17, 2025 | 57 days after the trade |
| Josh Gottheimer House · D-NJ | Partial sale | GMED Globus Medical, Inc. Class A Common Stock | $1,001 to $15k | Apr 9, 2025 | 35 days after the trade |
Transactions
The last 54 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 23, 2025 | Davidar David D director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | Huller Kelly SVP, GC, Corporate Secretary | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +40,000 | $0.00 | $0 | 40,000 | Mar 28, 2025 |
| Jan 23, 2025 | Lemaitre Dan director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | Norwalk Leslie V director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | Paul David C Executive Chairman | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +75,000 | $0.00 | $0 | 75,000 | Mar 28, 2025 |
| Jan 23, 2025 | Pfeil Keith W COO, CFO | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 28, 2025 |
| Jan 23, 2025 | RHOADS ANN D director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | Scavilla Daniel T President, CEO | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +140,000 | $0.00 | $0 | 140,000 | Mar 28, 2025 |
| Jan 23, 2025 | TOBIN JAMES R director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | Wolterman Dan director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | ZARRILLI STEPHEN T director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | Douglas Robert Andrew director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Jan 23, 2025 | DeFord John A director | AGrant or award Stock Option (Right to Buy Class A Common Stock)derivative | +15,000 | $0.00 | $0 | 15,000 | Mar 28, 2025 |
| Feb 28, 2025 | RHOADS ANN D director | SOpen-market sale Class A Common Stock10b5-1 | -7,500 | $78.68 | $590k | 35,384 | Mar 4, 2025 |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | MOption exercise Class A Common Stock10b5-1 | +5,833 | $49.65 | $290k | 5,833 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | MOption exercise Class A Common Stock10b5-1 | +8,334 | $53.27 | $444k | 14,167 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | SOpen-market sale Class A Common Stock10b5-1 | -12,501 | $88.17 | $1.1M | 1,666 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | SOpen-market sale Class A Common Stock10b5-1 | -1,666 | $89.17 | $149k | 0 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -5,833 | $0.00 | $0 | 0 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -8,334 | $0.00 | $0 | 833 | Jan 14, 2025 |
| Dec 2, 2024 | Huller Kelly SVP, GC, Corporate Secretary | MOption exercise Class A Common Stock10b5-1 | +2,500 | $24.21 | $61k | 2,500 | Dec 4, 2024 |
| Dec 2, 2024 | Huller Kelly SVP, GC, Corporate Secretary | SOpen-market sale Class A Common Stock10b5-1 | -2,500 | $87.00 | $218k | 0 | Dec 4, 2024 |
| Dec 2, 2024 | Huller Kelly SVP, GC, Corporate Secretary | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -2,500 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Nov 21, 2024 | Lemaitre Dan director | MOption exercise Class A Common Stock | +13,278 | $65.05 | $864k | 13,278 | Nov 25, 2024 |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | MOption exercise Class A Common Stock10b5-1 | +50,000 | $43.77 | $2.2M | 50,000 | Nov 25, 2024 |
| Nov 21, 2024 | Davidar David D director | SOpen-market sale Class A Common Stock10b5-1 | -13,234 | $85.00 | $1.1M | 523,041 | Nov 25, 2024 |
| Nov 21, 2024 | Davidar David D director | SOpen-market sale Class A Common Stockindirect: By Davidar Family Irrevocable Trust10b5-1 | -13,254 | $85.00 | $1.1M | 172,713 | Nov 25, 2024 |
| Nov 21, 2024 | Lemaitre Dan director | SOpen-market sale Class A Common Stock | -13,278 | $85.00 | $1.1M | 0 | Nov 25, 2024 |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | MOption exercise Class A Common Stock10b5-1 | +80,000 | $43.58 | $3.5M | 130,000 | Nov 25, 2024 |
| Nov 22, 2024 | Lemaitre Dan director | MOption exercise Class A Common Stock | +1,097 | $65.05 | $71k | 1,097 | Nov 25, 2024 |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | SOpen-market sale Class A Common Stock10b5-1 | -130,000 | $85.00 | $11M | 0 | Nov 25, 2024 |
| Nov 22, 2024 | Davidar David D director | SOpen-market sale Class A Common Stock10b5-1 | -6,766 | $85.00 | $575k | 516,275 | Nov 25, 2024 |
| Nov 22, 2024 | Lemaitre Dan director | SOpen-market sale Class A Common Stock | -1,097 | $85.02 | $93k | 0 | Nov 25, 2024 |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -50,000 | $0.00 | $0 | 0 | Nov 25, 2024 |
| Nov 22, 2024 | Davidar David D director | SOpen-market sale Class A Common Stockindirect: By Davidar Family Irrevocable Trust10b5-1 | -6,746 | $85.00 | $573k | 165,967 | Nov 25, 2024 |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -80,000 | $0.00 | $0 | 0 | Nov 25, 2024 |
| Nov 21, 2024 | Lemaitre Dan director | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative | -13,278 | $0.00 | $0 | 1,722 | Nov 25, 2024 |
| Nov 22, 2024 | Lemaitre Dan director | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative | -1,097 | $0.00 | $0 | 625 | Nov 25, 2024 |
| Nov 15, 2024 | Paul David C Executive Chairman | MOption exercise Class A Common Stock | +26,042 | $24.10 | $628k | 26,042 | Nov 20, 2024 |
| Nov 15, 2024 | Paul David C Executive Chairman | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative | -26,042 | $0.00 | $0 | 0 | Nov 20, 2024 |
| Nov 6, 2024 | Scavilla Daniel T President, CEO | MOption exercise Class A Common Stock10b5-1 | +30,000 | $26.27 | $788k | 30,000 | Nov 8, 2024 |
| Nov 6, 2024 | Huller Kelly SVP, GC, Corporate Secretary | MOption exercise Class A Common Stock10b5-1 | +5,000 | $24.21 | $121k | 5,000 | Nov 8, 2024 |
| Nov 6, 2024 | Scavilla Daniel T President, CEO | MOption exercise Class A Common Stock10b5-1 | +30,000 | $43.77 | $1.3M | 60,000 | Nov 8, 2024 |
| Nov 6, 2024 | Huller Kelly SVP, GC, Corporate Secretary | SOpen-market sale Class A Common Stock10b5-1 | -2,500 | $80.02 | $200k | 2,500 | Nov 8, 2024 |
| Nov 6, 2024 | Scavilla Daniel T President, CEO | SOpen-market sale Class A Common Stock10b5-1 | -60,000 | $80.02 | $4.8M | 0 | Nov 8, 2024 |
| Nov 6, 2024 | Huller Kelly SVP, GC, Corporate Secretary | SOpen-market sale Class A Common Stock10b5-1 | -2,500 | $82.00 | $205k | 0 | Nov 8, 2024 |
| Nov 6, 2024 | Scavilla Daniel T President, CEO | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | +30,000 | $0.00 | $0 | 0 | Nov 8, 2024 |
| Nov 6, 2024 | Huller Kelly SVP, GC, Corporate Secretary | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -5,000 | $0.00 | $0 | 2,500 | Nov 8, 2024 |
| Nov 6, 2024 | Scavilla Daniel T President, CEO | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | +30,000 | $0.00 | $0 | 50,000 | Nov 8, 2024 |
| Oct 16, 2024 | Davidar David D director | SOpen-market sale Class A Common Stock10b5-1 | -30,000 | $75.04 | $2.3M | 536,275 | Oct 18, 2024 |
| Oct 16, 2024 | Huller Kelly SVP, GC, Corporate Secretary | MOption exercise Class A Common Stock10b5-1 | +7,500 | $25.80 | $194k | 7,500 | Oct 18, 2024 |
| Oct 16, 2024 | Davidar David D director | SOpen-market sale Class A Common Stockindirect: By Davidar Family Irrevocable Trust10b5-1 | -20,000 | $75.03 | $1.5M | 185,967 | Oct 18, 2024 |
| Oct 16, 2024 | Huller Kelly SVP, GC, Corporate Secretary | SOpen-market sale Class A Common Stock10b5-1 | -7,500 | $75.02 | $563k | - | Oct 18, 2024 |
| Oct 16, 2024 | Huller Kelly SVP, GC, Corporate Secretary | MOption exercise Stock Option (Right to Buy Class A Common Stock)derivative10b5-1 | -7,500 | $0.00 | $0 | 0 | Oct 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Davidar David Ddirector
- DeFord John Adirector
- Douglas Robert Andrewdirector
- Huller KellySVP, GC, Corporate Secretary
- Lemaitre Dandirector
- Norwalk Leslie Vdirector
- Paul David CExecutive Chairman
- Pfeil Keith WCOO, CFO
- RHOADS ANN Ddirector
- Scavilla Daniel TPresident, CEO
- TOBIN JAMES Rdirector
- Wolterman Dandirector
- ZARRILLI STEPHEN Tdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.